Karyopharm (NASDAQ: KPTI) EVP sells shares for tax withholding

Rhea-AI Filing Summary

Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported an open-market sale of 4,604 shares of common stock at $9.4095 per share. This broker-assisted sale was executed under a durable automatic sale instruction plan to cover withholding taxes on vested restricted stock units and was not a discretionary trade. After the transaction, Cheng directly holds 107,317 shares.

Insider Trade Summary

Net Seller: 4,604 shares

Net Sell 1 txn

Insider Cheng Sohanya Roshan

Role EVP & Chief Commercial Officer

Sold 4,604 shs ($43K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,604	$9.4095	$43K

Holdings After Transaction: Common Stock — 107,317 shares (Direct)

Footnotes (1)

1. F1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 04:27 PM Learn about SEC filing dates

FAQ

What insider transaction did Karyopharm Therapeutics (KPTI) report on this Form 4?

Karyopharm Therapeutics reported that EVP & Chief Commercial Officer Sohanya Roshan Cheng sold 4,604 shares of common stock at $9.4095 per share. The transaction was a broker-assisted open-market sale related to tax withholding on vested restricted stock units.

Why did Karyopharm executive Sohanya Roshan Cheng sell 4,604 KPTI shares?

The 4,604-share sale by Sohanya Roshan Cheng was made to satisfy withholding tax liabilities from the vesting of restricted stock units. It was executed under a durable automatic sale instruction plan and specifically noted as not being a discretionary trade by the executive.

How many KPTI shares does the Karyopharm EVP hold after the reported sale?

Following the reported transaction, EVP & Chief Commercial Officer Sohanya Roshan Cheng directly holds 107,317 shares of Karyopharm Therapeutics common stock. This post-transaction ownership reflects the 4,604 shares sold to cover tax obligations tied to restricted stock unit vesting.

Was the Karyopharm (KPTI) insider share sale a discretionary trade?

No, the filing states the sale does not represent a discretionary trade by Sohanya Roshan Cheng. It was carried out under a durable automatic sale instruction plan and conducted as a broker-assisted sale solely to cover withholding taxes from restricted stock unit vesting.

What type of plan governed the Karyopharm EVP’s sale of 4,604 KPTI shares?

The sale was executed under a durable automatic sale instruction plan adopted on June 7, 2022. This plan directed a broker-assisted sale of shares when restricted stock units vested to cover the associated withholding tax liabilities, rather than reflecting an opportunistic market decision.

What was the price per share in the Karyopharm (KPTI) insider sale?

The 4,604 Karyopharm Therapeutics shares were sold at $9.4095 per share. This price applies to the broker-assisted open-market sale used to satisfy the executive’s withholding tax obligations created by the vesting of restricted stock units, as detailed in the Form 4 footnote.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cheng Sohanya Roshan

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		4,604	D	$9.4095	107,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.